Compare American International Group Inc (AIG) vs Viatris Inc (VTRS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American International Group Inc vs Viatris Inc — how do they compare? American International Group Inc trades at $80.26 (market cap $42.98B), while Viatris Inc trades at $16.49 (market cap $19.75B). The key difference: American International Group Inc is far larger — about 2.2× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| AIG | VTRS | |
|---|---|---|
Market Cap | $42.98B | $19.75B |
Sector | Financials | Health |
52-Week High | $86.59 | $17.39 |
52-Week Low | $71.89 | $8.74 |
Enterprise Value | $50.68B | $31.96B |
Dividend Yield | 2.47% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIG trades at $81.06, up 2.1% today, showing strong momentum with three consecutive quarterly earnings beats. The stock is supported by bullish technical signals and a consensus price target of $88.13. Recent executive appointments and the acquisition of Everest Colombia signal strategic growth initiatives. Revenue stabilized around $26.8B in 2025 with net income margin improving to 11.88%.
Outlook remains positive with earnings growth and expansion in Latin America offering upside potential. Risks include catastrophe exposure and competitive pressures. Analysts are predominantly neutral with 58.5% Hold ratings, suggesting cautious optimism amid solid fundamentals.
Viatris (VTRS) trades at $16.96, up 1.56% on the day and near its 52-week high of $17.53. The stock shows a bullish technical trend with consistent earnings beats in recent quarters. However, fundamentals reveal challenges, including a net loss of $3.51 billion in 2025 and negative profit margins, though revenue remains stable around $14.3 billion. Positive developments include a strong pipeline, with recent FDA acceptance of a new drug application for fast-acting meloxicam and positive Phase 3 results for VR-205.
The outlook is mixed; analyst consensus is a 'Hold' with a $20 price target, suggesting modest upside. Key opportunities lie in pipeline catalysts and debt reduction, but risks include persistent profitability issues, high debt levels, and competitive pressures. The stock's valuation metrics like P/S of 1.35 may appeal to value investors, but earnings sustainability is a concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American International Group Inc
American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. Its revenue is split roughly evenly between commercial and consumer lines.
Read more on AIG →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
